hrp0098p2-351 | Late Breaking | ESPE2024

Up to 5 years of once-weekly somatrogon treatment in pediatric patients with growth hormone deficiency: results from an open-label extension of a global Phase 3 study

Silverman Lawrence , Steelman Joel , Choe John , Stawerska Renata , Deal Cheri , Wajnrajch Michael , Thomas Marc , La Torre Daria , Phillip Moshe , Taylor Carrie , Wang Rong , Cara Jose

Objective: Somatrogon, a long-acting recombinant human growth hormone (rhGH) is approved as a once-weekly treatment for pediatric growth hormone deficiency (pGHD). This abstract describes the long-term efficacy and safety of somatrogon in patients with pGHD following up to 5 years of treatment in a global, Phase 3 study (NCT02968004).Methods: In the main study period, patients were randomized to receive either once-weekl...

hrp0095p1-432 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Effects of COVID-19 pandemic on serum vitamin D concentration in Korean children

Choi Jinjoo , Choe Yunsoo , Yang Seung

Purpose: Vitamin D deficiency (VDD) is very common nowadays in children as well as in adults, probably due to decreased exposure to sunlight. COVID-19 pandemic resulted in school closure and decreased outdoor activity in children, which lead to lower chance for exposure to sunlight. It was reported that the higher level of visceral fat was associated with the lower vitamin D levels in children. The aim of this study is whether body mass index (BMI) affect seru...

hrp0097p1-418 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Comparison of efficacy and safety of oral cholecalciferol administration at 4-week intervals and daily administration to correct vitamin D deficiency in adolescents

Choi Jinjoo , Choe Yunsoo , Yang Seung

Objectives: Vitamin D deficiency is prevalent in pediatric population. Since low compliance may inhibit appropriate vitamin D supplementation in daily dosing regimen, intermittent high dose administration may be considered. We aimed to evaluate the efficacy and safety of monthly administration of oral cholecalciferol compared with daily dosing regimen in adolescents with vitamin D deficiency.Methods: This retrospective s...

hrp0098p1-141 | Fat, Metabolism and Obesity 2 | ESPE2024

Assessment of Central Obesity and Body Mass Index in Youth Using a Non-Contact Radar Sensor

Choi Jinjoo , Choe Yunsoo , Yang Seung

Background: Central obesity in children is a significant risk factor for cardiovascular diseases, potentially more critical than BMI-defined obesity, and can persist into adolescence and adulthood. Measuring the Waist-to-Hip Ratio (WHR), an indicator of central obesity and associated health risks, typically requires direct measurement with a tape, which can be inconvenient and socially unacceptable. Therefore, non-contact anthropometric techniques to measure b...

hrp0098p1-172 | Growth and Syndromes 2 | ESPE2024

Impact of Feeding Types on Catch-Up Growth in Early Infancy Among Small-for-Gestational-Age Infants: A Nationwide Korean Study

Choi Jinjoo , Choe Yunsoo , Yang Seung

Purpose: This study aimed to compare growth patterns and the achievement of catch-up growth (CUG) in small-for-gestational-age (SGA) infants at four years of age, based on the type of feeding during the first 4-6 months, using nationwide data.Methods: We included full-term 42,295 SGA children (21,917 boys; 52%) who participated in the first (4-6 months), second (9-12 months), third (18-24 months), and fifth (42-48 months...

hrp0095p2-58 | Diabetes and Insulin | ESPE2022

Real-world use of continuous glucose monitoring and its effect on glycemic control among Korean children, adolescents, and young adults with type 1 diabetes

Lee Dahye , Choe Yunsoo , Jeong Lee Yun , Ho Shin Choong , Ah Lee Young

Background: The Korean National Health Insurance Service has started reimbursing the cost of continuous glucose monitoring (CGM) in type 1 diabetes (T1D) in 2019. We investigated the effect of CGM use on glycemic control among Korean children, adolescents, and young adults with T1D in a real-world setting.Method: We retrospectively reviewed the medical records of childhood-onset T1D patients aged < 30 years (n</em...

hrp0092s7.2 | Adrenal Insufficiency: New Mechanisms, New Therapies | ESPE2019

Novel Insights into the Pathophysiology of Adrenal Insufficiency Syndromes

Achermann John

Primary adrenal insufficiency (PAI) is an important diagnosis to make as it is potentially life-threatening and requires urgent treatment. Although most paediatric endocrinologists have experience of more common conditions such as congenital adrenal hyperplasia (CAH) and autoimmune adrenal insufficiency, more than 30 other genetics causes of PAI exist, as well as physical causes such as haemorrhage. Reaching a specific diagnosis for some of these rarer conditions can have impo...

hrp0082s5.1 | Novel Insights into Hypoadrenalism | ESPE2014

Aetiology of Congenital Hypoadrenalism

Achermann John

Congenital adrenal insufficiency is a potentially life-threatening condition that can present soon after birth in many different ways. The classic presentation is a salt-losing crisis due to mineralocorticoid insufficiency, often between a week and two of life, but babies with predominant glucocorticoid insufficiency can present with other features such as prolonged jaundice, hypoglycaemia and hyperpigmentation. Most children with congenital adrenal insufficiency present to em...

hrp0082wg3.1 | DSD | ESPE2014

Genetic Variation in Human SF-1 (NR5A1): Clinical Consequences for Individuals, Families and Populations

Achermann John

Steroidogenic factor-1 (SF-1, NR5A1) is a key regulator of adrenal and gonad development, and controls transcription of many genes in these endocrine axes. A role for SF-1/NR5A1 in human endocrine conditions was first established 15 years ago when rare individuals with adrenal hypoplasia and 46,XY DSD (testicular dysgenesis, Müllerian structures) were reported. Although it was felt that adrenal failure would be a key feature of SF-1 disruption, in the pa...

hrp0098s8.1 | Improving treatment strategies in Obesity | ESPE2024

Pharmacotherapy of Obesity

Wilding John

Recent years have seen rapid changes in the availability of new medical treatments as an adjunct to lifestyle support for adults, children and adolescents living with obesity. Although the GLP1 receptor agonist (RA) liraglutide 3 mg, given by daily subcutaneous injection, has been available for some time, the recent approval of semaglutide 2.4 mg weekly represents a major advance in efficacy. In clinical trials, semaglutide results in weight loss of 15% or more in more than ha...